4 results on '"Contreras-Gutierrez, Jose A."'
Search Results
2. National Burden and Trends for 29 Groups of Cancer in Mexico from 1990 to 2019: A Secondary Analysis of the Global Burden of Disease Study 2019.
- Author
-
Beltran-Ontiveros, Saul A., Contreras-Gutierrez, Jose A., Lizarraga-Verdugo, Erik, Gutierrez-Grijalva, Erick P., Lopez-Lopez, Kenia, Lora-Fierro, Emilio H., Trujillo-Rojas, Miguel A., Moreno-Ortiz, Jose M., Cardoso-Angulo, Diana L., Leal-Leon, Emir, Zatarain-Lopez, Jose R., Cuen-Diaz, Hector M., Montoya-Moreno, Marisol, Arce-Bojorquez, Brisceyda, Rochin-Teran, Juan L., Cuen-Lazcano, Daniel E., Contreras-Rodriguez, Victor A., Lascurain, Ricardo, Carmona-Aparicio, Liliana, and Coballase-Urrutia, Elvia
- Subjects
- *
GLOBAL burden of disease , *PUBLIC health , *TUMORS , *DEATH , *SECONDARY analysis - Abstract
Simple Summary: Cancer is a significant contributor to morbidity and mortality worldwide. The purpose of this study was to analyze the cancer burden and trends of 29 groups of malignant neoplasms in Mexico by sex and age from 1990 to 2019. In 2019, there were 222.1 thousand incident cases and 105.6 thousand deaths due to cancer in the general population. The number of new cases and deaths from the 29 cancer groups increased between 10% and 436% from 1990 to 2019, with different patterns by sex and age. Breast, cervical, and colorectal cancers were the leading causes of death among women, while prostate, lung, and colorectal cancers were the leading causes of death among men. In Mexico, malignant neoplasms were the third leading cause of death in 2019, causing significant health loss. The existence of gender disparities emphasizes the need for cancer-specific targeted prevention, diagnosis, and treatment. The global burden of cancer is on the rise, with varying national patterns. To gain a better understanding and control of cancer, it is essential to provide national estimates. Therefore, we present a comparative description of cancer incidence and mortality rates in Mexico from 1990 to 2019, by age and sex for 29 different cancer groups. Based on public data from the Global Burden of Disease Study 2019, we evaluated the national burden of cancer by analyzing counts and crude and age-standardized rates per 100,000 people with 95% uncertainty intervals for 2019 and trends using the annual percentage change from 1990 to 2019. In 2019, cancer resulted in 222,060 incident cases and 105,591 deaths. In 2019, the highest incidence of cancer was observed in non-melanoma skin cancer, prostate cancer, and breast cancer. Additionally, 53% of deaths were attributed to six cancer groups (lung, colorectal, stomach, prostate, breast, and pancreatic). From 1990 to 2019, there was an increasing trend in incidence and mortality rates, which varied by 10–436% among cancer groups. Furthermore, there were cancer-specific sex differences in crude and age-standardized rates. The results show an increase in the national cancer burden with sex-specific patterns of change. These findings can guide national efforts to reduce health loss due to cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019.
- Author
-
Beltran-Ontiveros, Saul A., Fernandez-Galindo, Martha A., Moreno-Ortiz, Jose M., Contreras-Gutierrez, Jose A., Madueña-Molina, Jesus, Arambula-Meraz, Eliakym, Leal-Leon, Emir, Becerril-Camacho, Delia M., Picos-Cardenas, Veronica J., Angulo-Rojo, Carla, Velazquez, Diana Z., Jimenez-Trejo, Francisco, Gallardo-Vera, Francisco, and Diaz, Daniel
- Subjects
AGE distribution ,GLOBAL burden of disease ,DISEASE incidence ,POPULATION geography ,COMPARATIVE studies ,CANCER patients ,SOCIODEMOGRAPHIC factors ,PROSTATE tumors - Abstract
Simple Summary: Worldwide, prostate cancer (PC) causes high morbidity and mortality. Thus, developing effective strategies for the prevention, diagnosis, and control of this disease is fundamental to providing updated and reliable estimations of the PC burden both nationally and subnationally. Herein, we analyzed data from the Global Burden of Disease study to estimate PC incidence and mortality, and their trends in Mexico at the national and subnational levels from 2000 to 2019. Our results show that PC was the top ranked cause of death among malign neoplasms in males from Mexico during 2019. Males from 70 to 79 years of age were the most affected by PC, and there was an increasing trend in the burden of this cancer. There was substantial subnational heterogeneity that suggested differential geographical patterns of change. These results provide both comprehensive and comparable estimates to assist the effort to reduce health loss due to PC. In 2019, the Global Burden of Disease (GBD) estimated that prostate cancer (PC) was the 16th most common cause of death globally in males. In Mexico, PC epidemiology has been studied by a number of metrics and over various periods, although without including the most up-to-date estimates. Herein, we describe and compare the burdens and trends of PC in Mexico and its 32 states from 2000 to 2019. For this study, we extracted online available data from the GBD 2019 to estimate the crude and age-standardized rates (ASR per 100,000 people) of the incidence and mortality of PC. In Mexico, PC caused 27.1 thousand (95% uncertainty intervals, 20.6–36.0 thousand) incident cases and 9.2 thousand (7.7–12.7 thousand) deaths in males of all ages in 2019. Among the states, Sinaloa had the greatest ASR of incidence, and Guerrero had the highest mortality. The burden of PC showed an increasing trend, although the magnitude of change differed between metrics and locations. We found both an increasing national trend and subnational variation in the burden of PC. Our results confirm the need for updated and timely estimates to design effective diagnostic and treatment campaigns in locations where the burden of PC is the highest. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. National Burden and Trends for 29 Groups of Cancer in Mexico from 1990 to 2019: A Secondary Analysis of the Global Burden of Disease Study 2019.
- Author
-
Beltran-Ontiveros SA, Contreras-Gutierrez JA, Lizarraga-Verdugo E, Gutierrez-Grijalva EP, Lopez-Lopez K, Lora-Fierro EH, Trujillo-Rojas MA, Moreno-Ortiz JM, Cardoso-Angulo DL, Leal-Leon E, Zatarain-Lopez JR, Cuen-Diaz HM, Montoya-Moreno M, Arce-Bojorquez B, Rochin-Teran JL, Cuen-Lazcano DE, Contreras-Rodriguez VA, Lascurain R, Carmona-Aparicio L, Coballase-Urrutia E, Gallardo-Vera F, and Diaz D
- Abstract
The global burden of cancer is on the rise, with varying national patterns. To gain a better understanding and control of cancer, it is essential to provide national estimates. Therefore, we present a comparative description of cancer incidence and mortality rates in Mexico from 1990 to 2019, by age and sex for 29 different cancer groups. Based on public data from the Global Burden of Disease Study 2019, we evaluated the national burden of cancer by analyzing counts and crude and age-standardized rates per 100,000 people with 95% uncertainty intervals for 2019 and trends using the annual percentage change from 1990 to 2019. In 2019, cancer resulted in 222,060 incident cases and 105,591 deaths. In 2019, the highest incidence of cancer was observed in non-melanoma skin cancer, prostate cancer, and breast cancer. Additionally, 53% of deaths were attributed to six cancer groups (lung, colorectal, stomach, prostate, breast, and pancreatic). From 1990 to 2019, there was an increasing trend in incidence and mortality rates, which varied by 10-436% among cancer groups. Furthermore, there were cancer-specific sex differences in crude and age-standardized rates. The results show an increase in the national cancer burden with sex-specific patterns of change. These findings can guide national efforts to reduce health loss due to cancer.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.